启迪药业(000590) - 2017 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2017 was ¥71,411,609.76, a decrease of 23.57% compared to ¥93,432,185.87 in the same period last year[8] - Net profit attributable to shareholders was ¥10,706,913.39, down 20.62% from ¥13,488,156.46 year-on-year[8] - Net profit excluding non-recurring items was ¥8,249,083.63, reflecting a significant decline of 38.77% from ¥13,472,788.07 in the previous year[8] - Basic and diluted earnings per share were both ¥0.0479, down 20.70% from ¥0.0604 in the previous year[8] - Operating revenue decreased by 55.16% to ¥46,107,660.61 compared to ¥102,822,533.58 in the previous period, primarily due to reduced sales from the traditional Chinese medicine segment[17] Cash Flow and Assets - Operating cash flow turned negative at -¥69,424,718.77, a drastic decrease of 5,456.28% compared to a positive cash flow of ¥1,296,137.03 in the same quarter last year[8] - The net cash flow from operating activities was -¥69,424,718.77, a decline of 5456.28% from ¥1,296,137.03 in the previous year, driven by reduced cash receipts from sales[18] - Cash and cash equivalents decreased by 64.48% to ¥43,578,768.31, primarily due to reduced cash flow from operating activities[15] - Cash received from other operating activities decreased by 44.56% to ¥1,571,219.74, mainly due to a reduction in government subsidies and other receivables[17] Assets and Liabilities - Total assets decreased by 12.03% to ¥554,822,665.49 from ¥630,679,185.12 at the end of the previous year[8] - Net assets attributable to shareholders increased by 4.10% to ¥271,676,532.09 from ¥260,969,618.70 at the end of the previous year[8] - Accounts receivable increased by 39.46% to ¥5,224,268.97, mainly due to an increase in receivables from the pharmaceutical segment[15] - Construction in progress rose by 71.20% to ¥25,962,861.21, attributed to investments in a major technical upgrade project[15] Financial Expenses and Impairments - Financial expenses decreased significantly by 342.89% to -¥886,208.64, attributed to a reduction in interest expenses[16] - Asset impairment losses dropped by 78.61% to ¥324,837.46, mainly due to a decrease in bad debt provisions for accounts receivable compared to the same period last year[16] Future Outlook and Plans - The company plans to issue non-public shares, which was approved by the China Securities Regulatory Commission on April 25, 2017[19] - The company expects significant changes in net profit for the first half of 2017 compared to the same period last year, but specific figures were not disclosed[22] Other Information - The company has not engaged in any securities or derivative investments during the reporting period[22][23] - There were no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[21]